Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 1Nephrotic Syndrome 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Bladder Cancer 1Kidney Diseases 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Carcinoma, Non-Small-Cell Lung 1Arthritis, Rheumatoid 1Amyloidosis 1

Interventions

Sunitinib 4avelumab 2Nutrition Assessment 2Blood Specimen Collection 2Axitinib 2trifluridine tipiracil drug combination 1trebananib 1spartalizumab 1pembrolizumab 1palbociclib 1etelcalcetide hydrochloride 1enzalutamide 1cabozantinib 1bicalutamide 1atezolizumab 1aldesleukin 1Valsartan 1VMBP protocol 1Stents 1Specimen Handling 1Sorafenib 1Sodium Bicarbonate 1Resistance Training 1Receptors, Androgen 1Plasma Exchange 1Pharmaceutical Preparations 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Nephrotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Diseases × Pharmaceutical Preparations × Genitourinary × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡